'Volume-expanded' hypertension: The effect of fluid overload and the role of the sympathetic nervous system in salt-dependent hypertension

Journal of Hypertension

Volumn 30, Issue 4, 2012, Pages 655-659

  Gavras, Irene ^a   Gavras, Haralambos ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood volume; central sympathetic nervous system; hyperadrenergic state; sodium

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CLONIDINE; PHENTOLAMINE; SODIUM ION;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; BRAIN STEM; GENETIC ENGINEERING; HEMODYNAMICS; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALT DEPENDENT HYPERTENSION; SODIUM RETENTION; WATER RETENTION;

EID: 84858707108     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834f6de1     Document Type: Review

References (60)

1. Guyton AC. Physiologic regulation of arterial pressure. Am J Cardiol 1961; 8401-407.
2. Guyton AC, Coleman TG, Cowley AW Jr, Manning RD Jr, Norman RA Jr, Ferguson JD. A systems analysis approach to understanding longrange arterial blood pressure control and hypertension. Circ Res 1974; 351:159-176.
3. Hall JE, Guyton AC, Salgado HC, McCaa RE, Balfe JW. Renal hemodynamics in acute and chronic angiotensin II hypertension. Am J Physiol 1978; 235:F174-F179. (Pubitemid 9166791)
4. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55:261-274.
5. Lebel M, Schalekamp MA, Beevers DG, Brown JJ, Davies DL, Fraser R, et al. Sodium and the renin-angiotensin system in essential hypertension and mineralocorticoid excess. Lancet 1974; 2:308-309.
6. Lund-Johansen P. Hemodynamic changes in late hypertension. In Onesti G, Kim KE, editors. Hypertension in the young, old. New York: Grune and Stratton; 1981. pp. 239.
7. Schalekamp MA, Birkenhager WH, Zaal GA, Kolsters G. Haemodynamic characteristics of low-renin hypertension. Clin Sci Mol Med 1977; 52:405-412.
8. Trippodo NC, Walsh GM, Frohlich ED. Fluid volumes during onset of spontaneous hypertension in rats. Am J Physiol 1978; 235: H52-H55. (Pubitemid 9164979)
9. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975; 36:300-309.
10. Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol 2010; 95:51-55.
11. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005; 45:766-722.
12. Guyton AC. The surprising kidney-fluid mechanism for pressure control: its infinite gain!. Hypertension 1990; 16:725-730.
13. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Sodium-induced elevation of blood pressure in the anephric state. Science 1980; 209:935-936. (Pubitemid 10011719)
14. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. Am J Physiol 1981; 240:H827-H831. (Pubitemid 11072747)
15. DiPette DJ, Gavras I, North WG, Brunner HR, Gavras H. Vasopressin in salt-induced hypertension of experimental renal insufficiency. Hypertension 1982; 4:125-130.
16. Gavras H. Possible mechanisms of sodium-dependent hypertension: volume expansion or vasoconstriction? Clin Exp Hypertens 1982; A4:737-749. (Pubitemid 12025380)
17. de Champlain J, Farley L, Cousineau D, van Ameringen MR. Circulating catecholamine levels in human and experimental hypertension. Circ Res 1976; 38:109-114.
18. Louis WJ, Doyle AE, Anavekar S. Plasma norepinephrine levels in essential hypertension. N Engl J Med 1973; 288:599-601.
19. Sever PS, Osikowska B, Birch M, Tunbridge RD. Plasma noradrenaline in essential hypertension. Lancet 1977; 1:1078-1081.
20. Lake CR, Kopin IJ, Ziegler MG, Coleman MD. Plasma catecholamines and neurogenic hypertension. N Engl J Med 1977; 297:53-54.
21. de Champlain J, Krakoff L, Axelrod J. Interrelationships of sodium intake, hypertension, and norepinephrine storage in the rat. Circ Res 1969; 24 (Suppl):75-92.
22. Reid JL, Zivin JA, Kopin IJ. Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res 1975; 37:569-579.
23. Murray RH, Luft FC, Bloch R, Weyman AE. Blood pressure responses to extremes of sodium intake in normal man. Proc Soc Exp Biol Med 1978; 159:432-436. (Pubitemid 9152554)
24. Nicholls MG, Kiowski W, Zweifler AJ, Julius s, Schork MA, Greenhouse J. Plasma norepinephrine variations with dietary sodium intake. Hypertension 1980; 2:29-32. (Pubitemid 10061183)
25. Chalmers JP. Brain amines and models of experimental hypertension. Circ Res 1975; 36:469-480.
26. Saavedra JM, Grobecker H, Axelrod J. Adrenaline-forming enzyme in brainstem: elevation in genetic and experimental hypertension. Science 1976; 191:483-484.
27. Saavedra JM, Correa FM, Iwai J. Discrete changes in adrenaline-forming enzyme activity in brain stem areas of genetic salt-sensitive hypertensive (Dahl) rats. Brain Res 1980; 193:299-303. (Pubitemid 10120989)
28. Feuerstein G, Zerbe RL, Ben-Ishay D, Kopin IJ, Jacobowitz DM. Catecholamines and vasopressin in hindbrain nuclei of hypertension prone and resistant rats. Brain Res 1982; 251:169-173. (Pubitemid 12005970)
29. Blessing WW, Sved AF, Reis DJ. Destruction of noradrenergic neurons in rabbit brainstem elevates plasma vasopressin, causing hypertension. Science 1982; 217:661-663. (Pubitemid 12041300)
30. Reis, DJ. Experimental evidence in support of a central neural imbalance hypothesis of hypertension. In Laragh JH, Buhler FR, Seldin DW, editors. Frontiers of hypertension research. New York: Springer-Verlag; 1981. pp. 341-343.
31. Young WS 3rd, Kuhar MJ. Noradrenergic alpha 1 and alpha 2 receptors: light microscopic autoradiographic localization. Proc Natl Acad Sci USA 1980; 77:1696-1700. (Pubitemid 10067422)
32. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981; 32:337-362.
33. Greenberg DA, U'Prichard DC, Sheehan P, Snyder SH. Alpha-noradrenergic receptors in the brain: differential effects of sodium on binding of [3H]agonists and [3H]antagonists. Brain Res 1978; 140:378-384. (Pubitemid 8247849)
34. Tsai BS, Lefkowitz RJ. Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol Pharmacol 1978; 14:540-548. (Pubitemid 8402461)
35. Glossman H, Libbecke F, Bellemann P, Sattler EL, Doell G. Ionic modulation of (-adrenoceptors. J Cardiovasc Pharmacol 1982; 4: 551-557.
36. Gavras H, Bain GT, Bland L, Vlahakos D, Gavras I. Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Res 1985; 343:113-119. (Pubitemid 16242902)
37. Benetos A, Bresnahan M, Gavras I, Gavras H. Central catecholamines and alpha-adrenoceptors in acute hypertension induced by intracerebroventricular hypertonic saline. J Hypertens 1987; 5:699-704. (Pubitemid 18029950)
38. Vlahakos D, Gavras H. Central sympathetic stimulation produced by saline application into the nucleus tractus solitarii area of conscious rats. Neurosci Lett 1988; 92:335-340.
39. Gavras H. How does salt raise blood pressure? A hypothesis. Hypertension 1986; 8:83-88. (Pubitemid 16161426)
40. Gavras H, Gavras I. Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens 1989; 7:601-606. (Pubitemid 19224223)
41. Insel PA. Adrenergic receptors: evolving concepts and clinical implications. N Engl J Med 1996; 334:580-585. (Pubitemid 26066133)
42. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 1996; 273:803-805. (Pubitemid 26271527)
43. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996; 273:801-803. (Pubitemid 26271526)
44. MacDonald E, Kobilka BK, Scheinin M. Gene targeting: homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997; 18:211-219. (Pubitemid 27283651)
45. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999; 56:154-161. (Pubitemid 29309824)
46. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the a2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999; 33:14-17. (Pubitemid 29061835)
47. Makaritsis KP, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, Gavras H. Sympathoinhibitory function of the a2A adrenergic receptor subtype. Hypertension 1999; 34:403-407. (Pubitemid 29426755)
48. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of a2-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000; 35:609-613. (Pubitemid 30108156)
49. Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of antisense oligodeoxynucleotide targeting of the a2B-adrenergic receptor messenger RNA in the central nervous system. Hypertension 2001; 38:1075-1080. (Pubitemid 34252808)
50. Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Central alpha2B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. J Hypertens 2003; 21:961-967. (Pubitemid 36677161)
51. Shenouda SM, Johns C, Gavras I, Gavras H. Long-term inhibition of the central alpha(2B)-adrenergic receptor gene via recombinant AAV-delivered antisense in hypertensive rats. Am J Hypertens 2006; 19:1135-1143. (Pubitemid 44633587)
52. Gavras I, Manolis AJ, Gavras H. The alpha2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001; 19:2115-2124. (Pubitemid 33135230)
53. Gavras I, Gavras H. Role of a2-adrenergic receptors in hypertension. Am J Hypertens 2001; 14:171S-177S.
54. Duka I, Gavras I, Johns C, Handy DE, Gavras H. Role of the postsynaptic alpha(2)-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen Pharmacol 2000; 34:101-106.
55. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005; 1:19-29. (Pubitemid 40828829)
56. Insel PA, Motulsky HJ. Minireview: a hypothesis linking intracellular sodium, membrane receptors and hypertension. Life Sci 1984;1009-1013. (Pubitemid 14154340)
57. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918. (Pubitemid 23006966)
58. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002; 20:3-9. (Pubitemid 34913395)
59. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2002; 20:933-939.
60. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57:846-851.